TransMedics Group's (TMDX) Overweight Rating Reiterated at Piper Sandler

TransMedics Group (NASDAQ:TMDX - Get Free Report)'s stock had its "overweight" rating reissued by stock analysts at Piper Sandler in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $145.00 price objective on the stock, up from their prior price objective of $125.00. Piper Sandler's target price indicates a potential upside of 6.94% from the stock's current price.

A number of other analysts have also commented on the stock. Canaccord Genuity Group reaffirmed a "buy" rating and set a $104.00 price objective on shares of TransMedics Group in a research note on Tuesday, March 11th. Oppenheimer upped their price objective on shares of TransMedics Group from $125.00 to $130.00 and gave the company an "outperform" rating in a research note on Friday, May 9th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a research note on Tuesday. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $128.70.

TransMedics Group Price Performance

NASDAQ TMDX traded up $5.78 on Wednesday, reaching $135.59. The company's stock had a trading volume of 807,619 shares, compared to its average volume of 1,358,921. TransMedics Group has a twelve month low of $55.00 and a twelve month high of $177.37. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The stock has a market cap of $4.59 billion, a PE ratio of 144.25 and a beta of 2.10. The firm's 50 day moving average is $98.76 and its two-hundred day moving average is $79.49.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.70 EPS for the quarter, beating analysts' consensus estimates of $0.29 by $0.41. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The company had revenue of $143.54 million during the quarter, compared to analyst estimates of $123.39 million. During the same period in the prior year, the firm earned $0.35 earnings per share. The business's quarterly revenue was up 48.2% on a year-over-year basis. As a group, sell-side analysts predict that TransMedics Group will post 1 EPS for the current year.

Insider Buying and Selling

In related news, Director Edward M. Basile sold 5,000 shares of the firm's stock in a transaction on Tuesday, May 27th. The stock was sold at an average price of $126.45, for a total value of $632,250.00. Following the completion of the transaction, the director now directly owns 2,866 shares of the company's stock, valued at $362,405.70. This trade represents a 63.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director David Weill sold 732 shares of the stock in a transaction on Friday, May 23rd. The stock was sold at an average price of $123.88, for a total value of $90,680.16. Following the transaction, the director now owns 12,134 shares of the company's stock, valued at $1,503,159.92. This represents a 5.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 11,732 shares of company stock worth $1,416,710. Insiders own 7.00% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. increased its stake in shares of TransMedics Group by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 3,635,919 shares of the company's stock valued at $226,700,000 after buying an additional 40,860 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in TransMedics Group by 244.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,113,082 shares of the company's stock worth $209,448,000 after purchasing an additional 2,209,996 shares during the period. FIL Ltd increased its position in TransMedics Group by 28.0% in the fourth quarter. FIL Ltd now owns 1,000,358 shares of the company's stock worth $62,372,000 after purchasing an additional 218,961 shares during the period. Braidwell LP acquired a new stake in TransMedics Group in the fourth quarter worth about $57,493,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in TransMedics Group by 16.6% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 903,086 shares of the company's stock worth $56,307,000 after purchasing an additional 128,474 shares during the period. 99.67% of the stock is currently owned by institutional investors and hedge funds.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.